Hikma Expects Generics To Hit A High In 2021

Announces Finasteride License From Almirall As Latest In A Series Of Deals

 
• By Dave Wallace

Hikma expects its generics business to hit the top end of its guidance for 2021, after recent launches and an improved product mix drove up its sales and operating margin. Meanwhile, the firm has announced a licensing agreement with Almirall for its Finjuve finasteride brand as the latest in a series of deals.

High performance dial
Hikma is forecasting a generics profit margin at the high end of its guidance • Source: Alamy

More from Earnings

More from Business